About this Research Topic
Alzheimer’s disease (AD) is a leading chronic neurodegenerative disorder and the primary cause of dementia, posing a significant global health threat. By 2040, it is projected that 81.1 million people worldwide will be affected by AD, with the number of dementia patients doubling every 20 years, leading to profound social, economic, and health challenges. The disease is characterized by two main hallmarks: the extracellular deposition of senile plaques composed of amyloid beta proteins and intraneuronal tangles formed with hyperphosphorylated tau units. Initially, it was believed that eliminating these plaques and tangles would halt neuroinflammation. However, later findings indicate that neuroinflammation precedes these hallmarks, contributing to severe neuronal death and synaptic dysfunction. Despite ongoing research, there are currently no approved drugs to treat neuroinflammation in AD. This inflammatory response, characterized by the production of cytokines, chemokines, and reactive oxygen species (ROS), is a complex process that requires further understanding to identify valid therapeutic targets. Although several small molecules and biomarkers are in clinical trials, many have failed, highlighting the urgent need for alternative methods and innovative therapeutic strategies.
This research topic aims to consolidate ongoing and future research on chemical approaches to combat neuroinflammation in Alzheimer's Disease. The primary objective is to explore and develop novel chemical molecules and therapeutic strategies that can effectively target neuroinflammatory processes. Key questions include identifying valid pharmacological targets, optimizing chemical compounds, and understanding the mechanistic roles of biomarkers in neuroinflammation. We also seek research that tests hypotheses related to the efficacy of receptor-based and structure-based chemical designs, as well as the potential of cutting-edge technologies like genome sequencing and CRISPR/Cas9 in regulating neuroinflammation.
To gather further insights into the chemical approaches combating neuroinflammation in Alzheimer's Disease, we welcome articles addressing, but not limited to, the following themes:
- Receptor-based or structure-based designing of chemical molecules against neuroinflammation
- Structure-Activity Relationship (SAR) based optimization of anti-inflammatory molecules
- Identification of neuroinflammatory changes involving the expression of different proteins and the development of inhibitors
- Pharmacophore analysis and identification of targets to change neuroinflammation
- Identification of novel biomarkers or mechanistic roles of biomarkers in neuroinflammatory changes
- Validation and comparison of novel biomarkers with existing biomarkers
- Cutting-edge research (e.g., genome sequencing, CRISPR/Cas9) based approaches for the regulation of neuroinflammation
- Epigenetic research studies involving neuroinflammatory changes
- Clinical/longitudinal research studies for the optimization of drugs to combat neuroinflammation in AD.
Topic Editor Dr. Dwaipayan Sen is employed by Astellas Gene Therapies. All other Topic Editors declare no competing interests with regards to the Research Topic subject
This research topic aims to consolidate ongoing and future research on chemical approaches to combat neuroinflammation in Alzheimer's Disease. The primary objective is to explore and develop novel chemical molecules and therapeutic strategies that can effectively target neuroinflammatory processes. Key questions include identifying valid pharmacological targets, optimizing chemical compounds, and understanding the mechanistic roles of biomarkers in neuroinflammation. We also seek research that tests hypotheses related to the efficacy of receptor-based and structure-based chemical designs, as well as the potential of cutting-edge technologies like genome sequencing and CRISPR/Cas9 in regulating neuroinflammation.
To gather further insights into the chemical approaches combating neuroinflammation in Alzheimer's Disease, we welcome articles addressing, but not limited to, the following themes:
- Receptor-based or structure-based designing of chemical molecules against neuroinflammation
- Structure-Activity Relationship (SAR) based optimization of anti-inflammatory molecules
- Identification of neuroinflammatory changes involving the expression of different proteins and the development of inhibitors
- Pharmacophore analysis and identification of targets to change neuroinflammation
- Identification of novel biomarkers or mechanistic roles of biomarkers in neuroinflammatory changes
- Validation and comparison of novel biomarkers with existing biomarkers
- Cutting-edge research (e.g., genome sequencing, CRISPR/Cas9) based approaches for the regulation of neuroinflammation
- Epigenetic research studies involving neuroinflammatory changes
- Clinical/longitudinal research studies for the optimization of drugs to combat neuroinflammation in AD.
Topic Editor Dr. Dwaipayan Sen is employed by Astellas Gene Therapies. All other Topic Editors declare no competing interests with regards to the Research Topic subject
Keywords: Alzheimer's disease, chronic neurodegenerative disorder, dementia, senile plaques, tau units, neuroinflammation
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
